AptaBio Therapeutics Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-27,991	-29,378	-12,062	-10,565
Depreciation & Amortization	532.1	531.35	539.11	484.62
Loss (Gain) From Sale of Investments	-20.11	583.55	244.29	2,494
Loss (Gain) on Equity Investments	385.79	583.5	4.19	-
Stock-Based Compensation	232.79	234.34	186.65	123.6
Other Operating Activities	12,177	12,478	-2,458	631.31
Change in Accounts Receivable	-487.56	-893.71	-	-
Change in Inventory	-151.66	-224.87	-	-
Change in Accounts Payable	115.03	1.87	-	-
Change in Other Net Operating Assets	-1,042	3,924	-549.77	-1.91
Operating Cash Flow	-16,250	-12,160	-14,095	-6,833
Capital Expenditures	-277.03	-240.16	-1,345	-1,041
Sale (Purchase) of Intangibles	-	-	-46.6	-10.36
Investment in Securities	9,603	13,521	-9,006	5,332
Other Investing Activities	-55.62	-55.62	60.15	27.66
Investing Cash Flow	9,270	12,854	-12,737	1,743
Long-Term Debt Issued	-	-	38,900	-
Long-Term Debt Repaid	-	-134.01	-127.85	-87.95
Net Debt Issued (Repaid)	-135.88	-134.01	38,772	-87.95
Issuance of Common Stock	-	-	-	589.2
Other Financing Activities	-32.7	-33.3	-19.2	-5.24
Financing Cash Flow	-168.58	-167.31	49,854	496.01
Foreign Exchange Rate Adjustments	-14.18	-1.19	5.07	16.76
Miscellaneous Cash Flow Adjustments	-0	-0	-0	0
Net Cash Flow	-7,162	525.33	23,027	-4,577
Free Cash Flow	-16,527	-12,400	-15,440	-7,874
Free Cash Flow Margin	-532.01%	-368.94%	-4767.39%	-16284.04%
Free Cash Flow Per Share	-669.37	-526.67	-692.42	-353.27
Cash Interest Paid	9.6	10.2	11.47	4.49
Cash Income Tax Paid	63.2	76.18	48.45	-34.01
Levered Free Cash Flow	-5,784	-1,924	-13,398	-
Unlevered Free Cash Flow	-3,922	201.3	-12,659	-
Change in Net Working Capital	-8,237	-12,623	1,429	-

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.